# Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification

> **NCT03580473** · PHASE2 · COMPLETED · sponsor: **EMS** · enrollment: 118 (actual)

## Conditions studied

- Ocular Inflammation
- Cataract

## Interventions

- **DRUG:** SATURNO II association
- **DRUG:** Vigadexa®

## Key facts

- **NCT ID:** NCT03580473
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-27
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-03-01
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580473, "Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03580473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*